Evaluation of seven drug metabolisms and clearances by cryopreserved human primary hepatocytes cultivated in microfluidic biochips
暂无分享,去创建一个
Cécile Legallais | Eric Leclerc | Régis Baudoin | Céline Brochot | Jessy Brocheton | E. Leclerc | C. Brochot | R. Baudoin | C. Legallais | J. Prot | Jean Matthieu Prot | Jessy Brocheton | Grégory Nicolas | Henri Benech | Grégory Nicolas | H. Bénech
[1] Cécile Legallais,et al. A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening. , 2011, International journal of pharmaceutics.
[2] Laurent Griscom,et al. Improvement of HepG2/C3a cell functions in a microfluidic biochip , 2011, Biotechnology and bioengineering.
[3] L. Schwarz,et al. Transcellular transport of fluorescein in hepatocyte monolayers: evidence for functional polarity of cells in culture. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[4] Shufang Zhang,et al. A robust high-throughput sandwich cell-based drug screening platform. , 2011, Biomaterials.
[5] A. Guillouzo,et al. Liver cell models in in vitro toxicology. , 1998, Environmental health perspectives.
[6] M. Yarmush,et al. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. , 2009, Biochemical pharmacology.
[7] Hugh A. Barton,et al. Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data , 2012, Drug Metabolism and Disposition.
[8] Hayley S. Brown,et al. Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies , 2007, Drug metabolism reviews.
[9] M. Toner,et al. Effects of oxygenation and flow on the viability and function of rat hepatocytes cocultured in a microchannel flat-plate bioreactor. , 2001, Biotechnology and bioengineering.
[10] John C Lipscomb,et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.
[11] M. Yarmush,et al. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. , 2010, Biochemical pharmacology.
[12] Peter J H Webborn,et al. Prediction of the Pharmacokinetics of Atorvastatin, Cerivastatin, and Indomethacin Using Kinetic Models Applied to Isolated Rat Hepatocytes , 2008, Drug Metabolism and Disposition.
[13] Thomas Hartung,et al. Chemical regulators have overreached , 2009, Nature.
[14] Yves Grandvalet,et al. Integrated Proteomic and Transcriptomic Investigation of the Acetaminophen Toxicity in Liver Microfluidic Biochip , 2011, PloS one.
[15] Laurent Griscom,et al. Behavior of HepG2/C3A cell cultures in a microfluidic bioreactor , 2011 .
[16] Robert Combes,et al. Toxicity testing: creating a revolution based on new technologies. , 2005, Trends in biotechnology.
[17] M. Toner,et al. Microfabricated grooved substrates as platforms for bioartificial liver reactors. , 2005, Biotechnology and bioengineering.
[18] L. Samson,et al. A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. , 2005, Current drug metabolism.
[19] F. Bois,et al. Zonation related function and ubiquitination regulation in human hepatocellular carcinoma cells in dynamic vs. static culture conditions , 2012, BMC Genomics.
[20] Cécile Legallais,et al. Metabolomics-on-a-chip and predictive systems toxicology in microfluidic bioartificial organs. , 2012, Analytical chemistry.
[21] Yau Yi Lau,et al. Development of a novel in vitro model to predict hepatic clearance using fresh, cryopreserved, and sandwich-cultured hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[22] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[23] D. Meijer,et al. Drug traffic in the hepatobiliary system. , 1996, Journal of hepatology.
[24] Paavo Honkakoski,et al. Inhibition and induction of human cytochrome P450 enzymes: current status , 2008, Archives of Toxicology.
[25] Don R. Maszle,et al. MCSim: A Monte Carlo Simulation Program , 1997 .
[26] M. Rissel,et al. Use of hepatocyte cultures for the study of hepatotoxic compounds. , 1997, Journal of hepatology.
[27] J Brian Houston,et al. Prediction of in vitro intrinsic clearance from hepatocytes: comparison of suspensions and monolayer cultures. , 2005, Drug metabolism and disposition: the biological fate of chemicals.
[28] E. Leclerc,et al. Metabolomics-on-a-chip and metabolic flux analysis for label-free modeling of the internal metabolism of HepG2/C3A cells. , 2012, Molecular bioSystems.
[29] Helmut Greim,et al. Toxicological comments to the discussion about REACH , 2006, Archives of Toxicology.
[30] W. Stigelman,et al. Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .
[31] J. Houston,et al. PREDICTION OF METABOLIC CLEARANCE USING CRYOPRESERVED HUMAN HEPATOCYTES: KINETIC CHARACTERISTICS FOR FIVE BENZODIAZEPINES , 2005, Drug Metabolism and Disposition.
[32] J Brian Houston,et al. Evaluation of Cryopreserved Human Hepatocytes as an Alternative in Vitro System to Microsomes for the Prediction of Metabolic Clearance , 2007, Drug Metabolism and Disposition.
[33] L. Griffith,et al. Functional behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor. , 2002, Tissue engineering.
[34] P. Beaune,et al. Biochemical and analytical development of the CIME cocktail for drug fate assessment in humans. , 2010, Rapid communications in mass spectrometry : RCM.
[35] Robert J Riley,et al. EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE , 2004, Drug Metabolism and Disposition.
[36] Melvin E. Andersen,et al. The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative , 2006, Archives of Toxicology.
[37] L. Griffith,et al. Tissue Engineering--Current Challenges and Expanding Opportunities , 2002, Science.
[38] N. Hewitt,et al. Studies comparing in vivo:in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures. , 2001, Drug metabolism and disposition: the biological fate of chemicals.
[39] Leslie M. Tompkins,et al. Mechanisms of cytochrome P450 induction , 2007, Journal of biochemical and molecular toxicology.